Trevi Therapeutics Inc [NASDAQ: TRVI] stock went on a downward path that fall over -3.00% on Monday, amounting to a one-week price increase of more than 0.40%.
Over the last 12 months, TRVI stock rose by 148.62%. The one-year Trevi Therapeutics Inc stock forecast points to a potential upside of 68.71. The average equity rating for TRVI stock is currently 1.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $642.52 million, with 99.89 million shares outstanding and 59.67 million shares in the current float. Compared to the average trading volume of 2.32M shares, TRVI stock reached a trading volume of 8671113 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Trevi Therapeutics Inc [TRVI]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TRVI shares is $20.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TRVI stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Trevi Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 28, 2025. While these analysts kept the previous recommendation, Raymond James dropped their target price from $9 to $29. The new note on the price target was released on March 10, 2025, representing the official price target for Trevi Therapeutics Inc stock. Previously, the target price had yet another raise from $8 to $25, while Needham kept a Buy rating on TRVI stock. On December 12, 2024, analysts increased their price target for TRVI shares from 6 to 7.50.
The Average True Range (ATR) for Trevi Therapeutics Inc is set at 0.48 The Price to Book ratio for the last quarter was 6.34, with the Price to Cash per share for the same quarter was set at 1.01.
TRVI Stock Performance Analysis:
Trevi Therapeutics Inc [TRVI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.40. With this latest performance, TRVI shares dropped by -8.48% in over the last four-week period, additionally plugging by 119.27% over the last 6 months – not to mention a rise of 148.62% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TRVI stock in for the last two-week period is set at 49.48, with the RSI for the last a single of trading hit 48.30, and the three-weeks RSI is set at 51.07 for Trevi Therapeutics Inc [TRVI]. The present Moving Average for the last 50 days of trading for this stock 6.30, while it was recorded at 6.32 for the last single week of trading, and 4.31 for the last 200 days.
Insight into Trevi Therapeutics Inc Fundamentals:
Trevi Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 15.38 and a Current Ratio set at 15.38.
TRVI Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TRVI. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Trevi Therapeutics Inc go to -13.45%.
Trevi Therapeutics Inc [TRVI] Institutonal Ownership Details
The top three institutional holders of TRVI stocks are: NEA MANAGEMENT COMPANY, LLC with ownership of 11.37 million shares, which is approximately 11.2532%. FRAZIER LIFE SCIENCES MANAGEMENT, L.P., holding 7.38 million shares of the stock with an approximate value of $$22.0 million in TRVI stocks shares; and FRAZIER LIFE SCIENCES MANAGEMENT, L.P., currently with $$14.98 million in TRVI stock with ownership which is approximately 4.9751%.
